The critical interaction of the metallopeptidase PHEX with heparan sulfate proteoglycans

International Journal of Biochemistry and Cell Biology

Volumn 40, Issue 12, 2008, Pages 2781-2792

  Barros, Nilana M T ^a   Nascimento, Fabio D ^a   Oliveira, Vitor ^a   Juliano, Maria Aparecida ^a   Juliano, Luiz ^a   Loisel, Thomas ^b   Nader, Helena B ^a   Boileau, Guy ^c   Tersariol, Ivarne L S ^d   Carmona, Adriana K ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b Enobia Pharma   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d UNIVERSIDADE DE MOGI DAS CRUZES   (Brazil)

Author keywords

Heparan sulfate; Heparin; Metallopeptidase; Phosphate regulating gene with homologies to endopeptidase on the X chromosome (PHEX); Proteoglycans

Indexed keywords

CHONDROITIN SULFATE; GLYCOSAMINOGLYCAN; HEPARIN BINDING PROTEIN; PHOSPHATE REGULATING NEUTRAL ENDOPEPTIDASE; PROTEOHEPARAN SULFATE; SODIUM CHLORIDE;

AFFINITY CHROMATOGRAPHY; ANIMAL CELL; ARTICLE; CELL MEMBRANE PERMEABILITY; CELL MIGRATION; CELL SURFACE; CHO CELL; CIRCULAR DICHROISM; CONFOCAL MICROSCOPY; DENATURATION; ENDOPLASMIC RETICULUM; ENZYME ACTIVITY; FLOW CYTOMETRY; FLUORESCENCE; FLUORESCENCE ANALYSIS; FLUORESCENCE RESONANCE ENERGY TRANSFER; HYDROLYSIS; INHIBITION KINETICS; NONHUMAN; OSTEOBLAST; PROTEIN INTERACTION;

ANIMALS; CHO CELLS; CHROMATOGRAPHY, AFFINITY; CIRCULAR DICHROISM; CRICETINAE; CRICETULUS; FLUORESCENCE RESONANCE ENERGY TRANSFER; HEPARAN SULFATE PROTEOGLYCANS; HEPARIN; HEPARITIN SULFATE; HYDROLYSIS; METALLOPROTEASES; PROTEIN BINDING; PROTEINS; PROTEOGLYCANS; RECOMBINANT PROTEINS; SUBSTRATE SPECIFICITY;

ALEXA;

EID: 51249091903     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biocel.2008.05.021     Document Type: Article

References (72)

1. Almeida P.C., Nantes I.L., Chagas J.R., Rizzi C.C., Faljoni-Alario A., Carmona E., Juliano L., Nader H.B., and Tersariol I.L. Cathepsin B activity regulation. Heparin-like glycosaminogylcans protect human cathepsin B from alkaline pH-induced inactivation. Journal of Biological Chemistry 276 (2001) 944-951
2. Andersson E., Rydengard V., Sonesson A., Morgelin M., Bjorck L., and Schmidtchen A. Antimicrobial activities of heparin-binding peptides. European Journal of Biochemistry 271 (2004) 1219-1226
3. Baici A., and Bradamante P. Interaction between human leukocyte elastase and chondroitin sulfate. Chemical-Biological Interactions 51 (1984) 1-11
4. Beck L., Soumounou Y., Martel J., Krishnamurthy G., Gauthier C., Goodyer C.G., and Tenenhouse H.S. Pex/PEX tissue distribution and evidence for a deletion in the 3' region of the Pex gene in X-linked hypophosphatemic mice. The Journal of Clinical Investigation 99 (1997) 1200-1209
5. Bernfield M., Götte M., Park P.W., Reizes O., Fitzgerald M.L., Lincecum J., and Zako M. Functions of cell surface heparan sulfate proteoglycans. Annual Review of Biochemistry 68 (1999) 729-777
6. Blydt-Hansen T.D., Tenenhouse H.S., and Goodyer P. PHEX expression in parathyroid gland and parathyroid hormone dysregulation in X-linked hypophosphatemia. Pediatric Nephrology 13 (1999) 607-611
7. Boileau G., Tenenhouse H.S., Desgroseillers L., and Crine P. Characterization of PHEX endopeptidase catalytic activity: identification of parathyroid-hormone-related peptide107-139 as a substrate and osteocalcin, PPi and phosphate as inhibitors. Biochemical Journal 355 (2001) 707-713
8. Boskey A.L., Spevak L., Doty S.B., and Rosenberg L. Effects of bone CS-proteoglycans, DS-decorin, and DS-biglycan on hydroxyapatite formation in a gelatin gel. Calcified Tissue International 61 (1997) 298-305
9. Brickman Y.G., Ford M.D., Gallagher J.T., Nurcombe V., Bartlett P.F., and Turnbull J.E. Structural modification of fibroblast growth factor-binding heparan sulfate at a determinative stage of neural development. Journal of Biological Chemistry 273 (1998) 4350-4359
10. Campos M., Couture C., Hirata I.Y., Juliano M.A., Loisel T.P., Crine P., Juliano L., Boileau G., and Carmona A.K. Human recombinant endopeptidase PHEX has a strict S1' specificity for acidic residues and cleaves peptides derived from fibroblast growth factor-23 and matrix extracellular phosphoglycoprotein. Biochemical Journal 373 (2003) 271-279
11. Capila I., and Linhardt R.J. Heparin-protein interactions. Angewandte Chemie (International ed. in English) 41 (2002) 390-412
12. Cardin A.D., and Weintraub H.J. Molecular modeling of protein-glycosaminoglycan interactions. Arteriosclerosis 9 (1989) 21-32
13. Conrad H.E. Heparin-binding proteins (1998), Academic Press, New York
14. Cool S.M., and Nurcombe V. The osteoblast-heparan sulfate axis: control of the bone cell lineage. International Journal of Biochemistry and Cell Biology 37 (2005) 1739-1745
15. Crine P., Dion N., and Boileau G. Endopeptidase 24:11: cell-surface peptidases in health and disease (1997), Bios Scientific Publishers Ltd., Oxford
16. Daphna E.M., Michaela S., Eynat P., Irit A., and Rimon S. Association of myeloperoxidase with heparin: oxidative inactivation of proteins on the surface of endothelial cells by the bound enzyme. Molecular Cellular Biochemistry 183 (1998) 55-61
17. Dietrich C.P., Tersariol I.L., Toma L., Moraes C.T., Porcionatto M.A., Oliveira F.W., and Nader H.B. Structure of heparan sulfate: identification of variable and constant oligosaccharide domains in eight heparan sulfates of different origins. Cellular and Molecular Biology 44 (1998) 417-429
18. Du L., Desbarats M., Viel J., Glorieux F.H., Cawthorn C., and Ecarot B. cDNA cloning of the murine Pex gene implicated in X-linked hypophosphatemia and evidence for expression in bone. Genomics 36 (1996) 22-28
19. Ecarot B., and Desbarats M. 1,25-(OH)2D3 down-regulates expression of Phex, a marker of the mature osteoblast. Endocrinology 140 (1999) 1192-1199
20. Econs M., and Francis F. Positional cloning of the PEX gene: new insights into the pathophysiology of X-linked hypophosphatemic rickets. American Journal of Physiology 273 (1997) F489-F498
21. Esko J.D., and Lindahl U. Molecular diversity of heparan sulfate. Journal of Clinical Investigation 108 (2001) 169-173
22. Fisher M.C., Li Y., Seghatoleslami M.R., Dealy C.N., and Kosher R.A. Heparan sulfate proteoglycans including syndecan-3 modulate BMP activity during limb cartilage differentiation. Matrix Biology 25 (2006) 27-39
23. Goldberg M., Septier D., Rapoport O., Iozzo R.V., Young M.F., and Ameye L.G. Targeted disruption of two small leucine-rich proteoglycans, biglycan and decorin, excerpts divergent effects on enamel and dentin formation. Calcified Tissue International 77 (2005) 297-310
24. Hallgren J., Spillmann D., and Pejler G. Structural requirements and mechanism for heparin-induced activation of a recombinant mouse mast cell tryptase, mouse mast cell protease-6: formation of active tryptase monomers in the presence of low molecular weight heparin. Journal of Biological Chemistry 276 (2001) 42774-42781
25. Handel T.M., Johnson Z., Crown S.E., Lau E.K., and Proudfoot A.E. Regulation of protein function by glycosaminoglycans-as exemplified by chemokines. Annual Review of Biochemistry 74 (2005) 385-410
26. 3 within the N-terminal domain of glucosidase I contains ER targeting information but is not required absolutely for ER localization. Glycobiology 13 (2003) 159-168
27. Hardwick K.G., and Pelham H.R. SED5 encodes a 39-kDa integral membrane protein required for vesicular transport between the ER and the Golgi complex. Journal of Cell Biology 119 (1992) 513-521
28. Hileman R.E., Fromm J.R., Weiler J.M., and Linhardt R.J. Glycosaminoglycan-protein interactions: definition of consensus sites in glycosaminoglycan binding proteins. Bioessays 20 (1998) 156-167
29. Gasteiger E., Hoogland C., Gattiker A., Duvaud S., Wilkins M.R., Appel R.D., and Bairoch A. Protein identification and analysis tools on the ExPASy server: the proteomics protocols handbook (2005), Human Press, USA. http://www.expasy.org/tools/pi_tool.html
30. Irie A., Habuchi H., Kimata K., and Sanai Y. Heparan sulfate is required for bone morphogenetic protein-7 signaling. Biochemical and Biophysical Research Communications 308 (2003) 858-865
31. Jentoft N. Why are proteins O-glycosylated?. Trends in Biochemical Sciences 15 (1990) 291-294
32. Jiang H., Liu X.Y., Zhang G., and Li Y. Kinetics and template nucleation of self-assembled hydroxyapatite nanocrystallites by chondroitin sulfate. Journal of Biological Chemistry 280 (2005) 42061-42066
33. Jiao X., Billings P.C., O'Connell M.P., Kaplan F.S., Shore E.M., and Glaser D.L. Heparan sulfate proteoglycans (HSPGs) modulate BMP2 osteogenic bioactivity in C2C12 cells. Journal of Biological Chemistry 282 (2007) 1080-1086
34. Jonsson K.B., Zahradnikm R., Larsson T., White K.E., Sugimoto T., Imanishi Y., Yamamoto T., Hampson G., Koshiyama H., Ljunggren O., Oba K., Yang I.M., Miyauchi A., Econs M.J., Lavigne J., and Juppner H.N. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. New England Journal of Medicine 348 (2003) 1656-1663
35. Kato K., Jeanneau C., Tarp M.A., Benet-Pagès A., Lorenz-Depiereux B., Mandel U., Strom T.M., and Clause H. Polypeptide GalNAc-transferase T3 and familial tumoral calcinosis. Secretion of fibroblast growth factor 23 requires O-glycosilation. Journal of Biological Chemistry 281 (2006) 18370-18377
36. Kolset S.O., and Gallagher J.T. Proteoglycans in haemopoietic cells. Biochimica et Biophysica Acta 1032 (1990) 191-211
37. Kolset S.O., Prydz K., and Pejler G. Intracellular proteoglycans. Biochemical Journal 379 (2004) 217-227
38. Kolset S.O., Voung T.T., and Orydz K. Apical secretion of chondroitin sulphate in polarized Madin-Darby canine kidney (MDCK) cells. Journal of Cell Science 112 (1999) 1797-1801
39. Li Z., Hou W.S., and Bromme D. Collagenolytic activity of cathepsin K is specifically modulated by cartilage-resident chondroitin sulfates. Biochemistry 39 (2000) 529-536
40. Lindahl U., Lidholt K., Spillmann D., and Kjellen L. More to "heparin" than anticoagulation. Thrombosis Research 75 (1994) 1-32
41. Lipman M.L., Panda D., Bennett H.P., Henderson J.E., Shane E., Shen Y., Goltzman D., and Karaplis A.C. Cloning of human PEX cDNA. Expression, subcellular localization, and endopeptidase activity. Journal of Biological Chemistry 273 (1998) 13729-13737
42. Liu S., Guo R., Simpson L.G., Xiao Z.S., Burnham C.E., and Quarles L.D. Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. Journal of Biological Chemistry 278 (2003) 37419-37426
43. Liu S., Tang W., Zhou J., Stubbs J.R., Luo Q., Pi M., and Quarles L.D. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. Journal of the American Society of Nephrology 17 (2006) 1305-1315
44. Manton K.J., Leong D.F., Cool S.M., and Nurcombe V. Disruption of heparan and chondroitin sulfate signaling enhances mesenchymal stem cell-derived osteogenic differentiation via bone morphogenetic protein signaling pathways. Stem Cells 25 (2007) 2845-2854
45. Marsh W.L. Molecular biology of blood groups: cloning the Kell gene. Transfusion 32 (1992) 98-101
46. Martin A., David V., Laurence J.S., Schwarz P.M., Lafer E.M., Hedge A.M., and Rowe P.S. Degradation of MEPE, DMP1, and release of SIBLING ASARM-peptides (minhibins): ASARM-peptide(s) are directly responsible for defective mineralization in HYP. Endocrinology 149 (2008) 1757-1772
47. Mellman I., Fuchs R., and Helenius A. Acidification of the endocytic and exocytic pathways. Annual Review of Biochemistry 55 (1986) 663-700
48. Mertens G., Van der Schueren B., van den Berghe H., and David G. Heparan sulfate expression in polarized epithelial cells: the apical sorting of glypican (GPI-anchored proteoglycan) is inversely related to its heparan sulfate content. Journal of Cell Biology 132 (1996) 487-497
49. Miao D., Bai X., Panda D., McKee M., Karaplis A., and Goltzman D. Osteomalacia in hyp mice is associated with abnormal PHEX expression and with altered bone matrix protein expression and deposition. Endocrinology 142 (2001) 926-939
50. Molteni A., Modrowski D., Hott M., and Marie P.J. Alterations of matrix- and cell-associated proteoglycans inhibit osteogenesis and growth response to fibroblast growth factor-2 in cultured rat mandibular condyle and calvaria. Cell and Tissue Research 295 (1999) 523-536
51. Nascimento F.D., Rizzi C.C., Nantes I.L., Stefe I., Turk B., Carmona A.K., Nader H.B., Juliano L., and Tersariol I.L. Cathepsin X binds to cell surface heparan sulfate proteoglycans. Archives of Biochemistry and Biophysics 436 (2005) 323-332
52. Ornitz D.M. FGFs, heparan sulfate and FGFRs: complex interactions essential for development. Bioessays 22 (2000) 108-112
53. Pejler G. Lactoferrin regulates the activity of heparin proteoglycan-bound mast cell chymase: characterization of the binding of heparin to lactoferrin. Biochemical Journal 320 (1996) 897-903
54. Pejler G., Winberg J.O., Vuong T.T., Henningsson F., Uhlin- Hansen L., Kimata K., and Kolset S.O. Secretion of macrophage urokinase plasminogen activator is dependent on proteoglycans. European Journal Biochemistry 270 (2003) 3971-3980
55. Raja S.M., Wang B., Dantuluri M., Desai U.R., Demeler B., Spiegel K., Metkar S.S., and Froelich C.J. Cytotoxic cell granule-mediated apoptosis. Characterization of the macromolecular complex of granzyme B with serglycin. Journal of Biological Chemistry 277 (2002) 49523-49530
56. Sabbagh Y., Boileau G., Campos M., Carmona A.K., and Tenenhouse H.S. Structure and function of disease-causing missense mutations in the PHEX gene. Journal of Clinical Endocrinology & Metabolism 88 (2003) 2213-2222
57. Sayama S., Iozzo R.V., Lazarus G.S., and Schechter N.M. Human skin chymotrypsin-like proteinase chymase. Subcellular localization to mast cell granules and interaction with heparin and other glycosaminoglycans. Journal of Biological Chemistry 262 (1987) 6808-6815
58. Shimada T., Mizutani S., Muto T., Yoneya T., Hino R., Takeda S., Takeuchi Y., Fujita T., Fukumoto S., and Yamashita T. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proceedings of the National Academy of Sciences USA 98 (2001) 6500-6505
59. Shimada T., Muto T., Urakawa I., Yoneya T., Yamazaki Y., Okawa K., Takeuchi Y., Fujita T., Fukumoto S., and Yamashita T. Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinolology 143 (2002) 3179-3182
60. Sobel M., Soler D.F., Kermode J.C., and Harris R.B. Localization and characterization of a heparin binding domain peptide of human von Willebrand factor. Journal of Biological Chemistry 267 (1992) 8857-8862
61. Teasdale R.D., and Jackson M.R. Signal-mediated sorting of membrane proteins between the endoplasmic reticulum and the Golgi apparatus. Annual Review of Cell and Developmental Biology 12 (1996) 27-54
62. Tenenhouse H.S., and Econs M.J. Disease-causing missense mutations in the PHEX gene interfere with membrane targeting of the recombinant protein. Mendelian hypophosphatemias: the metabolic and molecular basis of inherited disease (2001), McGraw Hill Book Co., NY
63. Tenenhouse H.S. Phosphate transport: molecular basis, regulation and pathophysiology. The Journal of Steroid Biochemistry and Molecular Biology 103 (2007) 572-577
64. The ADHR Consortium. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nature Genetics 26 (2000) 345-48.
65. The HYP Consortium. A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. Nature Genetics 11 (1995) 130-36.
66. Thompson D.L., Sabbagh Y., Tenenhouse H.S., Roche P.C., Drezner M.K., Salisbury J.L., Grande J.P., Poescha E.M.E., and Kumar R. Ontogeny of Phex/PHEX protein expression in mouse embryo and subcellular localization in osteoblasts. Journal of Bone and Mineral Research 17 (2002) 311-320
67. Turner A.J. Endothelin-converting enzymes: cell-surface peptidases in health and disease (1997), Bios Scientific Publishers Ltd., Oxford
68. Vargas M.A., St-Louis M., Desgroseillers L., Charli J.L., and Boileau G. Parathyroid hormone-related protein(1-34) regulates Phex expression in osteoblasts through the protein kinase A pathway. Endocrinology 144 (2003) 4876-4885
69. Wieland F., and Harter C. Mechanisms of vesicle formation: insights from the COP system. Current Opinion in Cell Biology 11 (1999) 440-446
70. Xiao Z.S., Crenshaw M., Guo R., Nesbitt T., Drezner M.K., and Quarles L.D. Intrinsic mineralization defect in Hyp mouse osteoblasts. American Journal of Physiology 275 (1998) 700-708
71. Yuan B., Takaiwa M., Clemens T.L., Feng J.Q., Kumar R., Rowe P.S., Xie Y., and Drezner M.K. Aberrant Phex function in osteoblasts and osteocytes alone underlies murine X-linked hypophosphatemia. Journal of Clinical Investigation 118 (2008) 722-734
72. Zernichow L., Dalen K.T., Prydz K., Winberg J.O., and Kolset S.O. Secretion of proteases in serglycin transfected Madin-Darby canine kidney cells. FEBS Journal 273 (2006) 536-547